LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MCF7 | Sirolimus | 10.0 | uM | LJP6 | 3 | L13 | 72 | hr | 1235 | 2864 | 4156 | 0.6891 | 0.5576 |
| MCF7 | Sorafenib | 10.0 | uM | LJP6 | 1 | B07 | 72 | hr | 1235 | 1776 | 4156 | 0.4273 | 0.1851 |
| MCF7 | Sorafenib | 10.0 | uM | LJP6 | 2 | B07 | 72 | hr | 1235 | 1624 | 4156 | 0.3907 | 0.1331 |
| MCF7 | Sorafenib | 10.0 | uM | LJP6 | 3 | B07 | 72 | hr | 1235 | 1537 | 4156 | 0.3698 | 0.1033 |
| MCF7 | SU11274 | 10.0 | uM | LJP5 | 1 | J07 | 72 | hr | 1235 | 1521 | 4156 | 0.3660 | 0.0978 |
| MCF7 | SU11274 | 10.0 | uM | LJP5 | 2 | J07 | 72 | hr | 1235 | 1587 | 4156 | 0.3818 | 0.1204 |
| MCF7 | SU11274 | 10.0 | uM | LJP5 | 3 | J07 | 72 | hr | 1235 | 1620 | 4156 | 0.3898 | 0.1317 |
| MCF7 | Fedratinib | 10.0 | uM | LJP5 | 1 | L01 | 72 | hr | 1235 | 770 | 4156 | 0.1853 | -0.1593 |
| MCF7 | Fedratinib | 10.0 | uM | LJP5 | 2 | L01 | 72 | hr | 1235 | 646 | 4156 | 0.1554 | -0.2018 |
| MCF7 | Fedratinib | 10.0 | uM | LJP5 | 3 | L01 | 72 | hr | 1235 | 532 | 4156 | 0.1280 | -0.2408 |
| MCF7 | TGX221 | 10.0 | uM | LJP5 | 1 | H19 | 72 | hr | 1235 | 3605 | 4156 | 0.8674 | 0.8113 |
| MCF7 | TGX221 | 10.0 | uM | LJP5 | 2 | H19 | 72 | hr | 1235 | 3777 | 4156 | 0.9088 | 0.8702 |
| MCF7 | TGX221 | 10.0 | uM | LJP5 | 3 | H19 | 72 | hr | 1235 | 3944 | 4156 | 0.9490 | 0.9274 |
| MCF7 | Torin1 | 10.0 | uM | LJP6 | 1 | O13 | 72 | hr | 1235 | 1085 | 4156 | 0.2611 | -0.0515 |
| MCF7 | Torin1 | 10.0 | uM | LJP6 | 2 | O13 | 72 | hr | 1235 | 1067 | 4156 | 0.2567 | -0.0577 |
| MCF7 | Torin1 | 10.0 | uM | LJP6 | 3 | O13 | 72 | hr | 1235 | 1263 | 4156 | 0.3039 | 0.0095 |
| MCF7 | Torin2 | 10.0 | uM | LJP5 | 1 | I19 | 72 | hr | 1235 | 948 | 4156 | 0.2281 | -0.0984 |
| MCF7 | Torin2 | 10.0 | uM | LJP5 | 2 | I19 | 72 | hr | 1235 | 1016 | 4156 | 0.2445 | -0.0751 |
| MCF7 | Torin2 | 10.0 | uM | LJP5 | 3 | I19 | 72 | hr | 1235 | 867 | 4156 | 0.2086 | -0.1261 |
| MCF7 | Tozasertib | 10.0 | uM | LJP5 | 1 | B13 | 72 | hr | 1235 | 1347 | 4156 | 0.3241 | 0.0382 |
| MCF7 | Tozasertib | 10.0 | uM | LJP5 | 2 | B13 | 72 | hr | 1235 | 1388 | 4156 | 0.3340 | 0.0523 |
| MCF7 | Tozasertib | 10.0 | uM | LJP5 | 3 | B13 | 72 | hr | 1235 | 1221 | 4156 | 0.2938 | -0.0049 |
| MCF7 | Trametinib | 10.0 | uM | LJP5 | 1 | P19 | 72 | hr | 1235 | 2050 | 4156 | 0.4932 | 0.2789 |
| MCF7 | Trametinib | 10.0 | uM | LJP5 | 2 | P19 | 72 | hr | 1235 | 2540 | 4156 | 0.6111 | 0.4467 |
| MCF7 | Trametinib | 10.0 | uM | LJP5 | 3 | P19 | 72 | hr | 1235 | 2549 | 4156 | 0.6133 | 0.4498 |